Purpose
To characterize the 12-month intraocular pressure (IOP)-lowering efficacy of selective laser trabeculoplasty (SLT) as sole therapy for primary open-angle glaucoma (POAG) in an Afro-Caribbean population.
Design
Stepped-wedge trial.
Methods
Subjects in St. Lucia and Dominica with established POAG were randomized to prompt washout of IOP-lowering medications followed by SLT, 3-month delay followed by washout and SLT, or 6-month delay followed by washout and SLT. Baseline IOP was obtained on two different days after washout. Bilateral 360-degree SLT was performed in one session. Post-treatment assessments took place 1 hour, 1 week, and 3, 6, 9, and 12 months post-SLT. The main outcome measure was SLT success (defined as IOP ≤ target IOP in both eyes) at 12 months. Target IOP was a 20% or greater reduction in IOP from post-washout baseline.
Results
Overall, 72 underwent SLT treatment. Mean IOP at enrollment was 15.4 ± 3.6 mmHg in right eyes and 15.4 ± 3.6 mmHg in left eyes, which rose to 21.0 ± 3.3 mmHg and 20.9 ± 3.0 mmHg, respectively, after washout. Mean IOP at 3, 6, 9 and 12 months ranged from 12.5 mmHg to 14.5 mmHg (29.7% to 39.5%; p<0.0001 in each eye at each time point). The 12-month success rate was 78%. Transient photophobia and discomfort were common.
Conclusions
SLT monotherapy safely provides significant IOP reduction in Afro-Caribbean eyes with POAG. This treatment can play a significant role in preventing glaucoma vision loss and blindness in people of African descent living in resource-limited regions.